Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Paclitaxel
Drug ID BADD_D01653
Description Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Indications and Usage Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
Marketing Status approved; vet_approved
ATC Code L01CD01
DrugBank ID DB01229
KEGG ID D00491
MeSH ID D017239
PubChem ID 36314
TTD Drug ID D0C4RB
NDC Product Code 0703-3213; 52222-0001; 65129-1308; 68083-179; 69539-159; 62422-0004; 68001-516; 68083-178; 0703-4768; 68554-0061; 46708-622; 47781-595; 62332-621; 62332-622; 63323-763; 72205-063; 60505-6230; 62332-620; 72205-062; 0517-4300; 0703-3216; 0703-3218; 17359-3055; 63126-902; 69539-158; 72205-061; 17359-4056; 49452-4961; 51446-0110; 59651-605; 0703-4764; 51446-0120; 46708-620; 61703-342; 68083-180; 0703-3217; 17359-4040; 62422-0002; 69539-157; 70860-215; 42533-111; 54893-0007; 65129-2039; 69443-022; 16714-137; 68817-134; 70860-200; 17359-4055; 65892-002; 24979-710; 46708-621
UNII P88XT4IS4D
Synonyms Paclitaxel | Anzatax | NSC-125973 | NSC 125973 | NSC125973 | Taxol | Taxol A | Bris Taxol | Taxol, Bris | Paclitaxel, (4 alpha)-Isomer | Paxene | Praxel | 7-epi-Taxol | 7 epi Taxol | Onxol
Chemical Information
Molecular Formula C47H51NO14
CAS Registry Number 33069-62-4
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6) O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rhinitis allergic10.01.04.003; 22.04.04.003--
Rhinorrhoea22.12.03.021--
Scintillating scotoma17.17.02.007; 06.02.06.005--Not Available
Scleroderma23.03.02.005; 15.06.01.002; 10.04.07.0010.000448%Not Available
Screaming19.04.02.020; 08.01.03.0990.000246%Not Available
Second primary malignancy16.16.01.0140.000336%
Seizure17.12.03.001--
Sense of oppression08.01.09.0200.000336%Not Available
Sensory disturbance17.02.07.006--Not Available
Sensory loss17.02.07.007--Not Available
Sepsis11.01.11.003--
Septic shock24.06.02.011; 11.01.11.004--Not Available
Shock24.06.02.0020.000672%Not Available
Sinus bradycardia02.03.03.0090.000336%
Sinus congestion22.04.06.001--Not Available
Sinus tachycardia02.03.03.010--
Sinusitis22.07.03.007; 11.01.13.005--
Skin discolouration23.03.03.005--Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin fissures23.03.03.0080.000280%Not Available
Skin hyperpigmentation23.05.01.0030.000280%
Skin hypertrophy23.01.04.002--Not Available
Skin lesion23.03.03.010--Not Available
Skin necrosis23.03.03.0110.000280%Not Available
Skin reaction23.03.03.013; 10.01.03.0190.000828%Not Available
Skin ulcer24.04.03.007; 23.07.03.0030.000616%
Skin warm23.03.03.0140.000112%Not Available
Small cell lung cancer22.08.01.013; 16.19.08.0030.000168%Not Available
Small intestinal obstruction07.13.06.0010.000336%
The 16th Page    First    Pre   16 17 18 19 20    Next   Last    Total 27 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene